Prior Presumed Coronavirus Infection Reduces COVID-19 Risk: A Cohort Study
Overview
Affiliations
Background: Immunological cross-reactivity between common cold coronaviruses (CCC) and SARS-CoV-2 might account for the reduced incidence of COVID-19 in children. Evidence to support speculation includes in vitro evidence for humoral and cellular cross-reactivity with SARS-CoV-2 in specimens obtained before the pandemic started.
Method: We used retrospective health insurance enrollment records, claims, and laboratory results to assemble a cohort of 869,236 insured individuals who had a PCR test for SARS-CoV-2. We estimated the effects of having clinical encounters for various diagnostic categories in the year preceding the study period on the risk of a positive test result.
Findings: After adjusting for age, gender and care seeking behavior, we identified that individuals with diagnoses for common cold symptoms, including acute sinusitis, bronchitis, or pharyngitis in the preceding year had a lower risk of testing positive for SARS-CoV-2 (OR=0.76, 95%CI=0.75, 0.77). No reduction in the odds of a positive test for SARS-CoV-2 was seen in individuals under 18 years. The reduction in odds in adults remained stable for four years but was strongest in those with recent common cold symptoms.
Interpretation: While this study cannot attribute this association to cross-immunity resulting from a prior CCC infection, it is one potential explanation. Regardless of the cause, the reduction in the odds of being infected by SARS-CoV-2 among those with a recent diagnosis of common cold symptoms may have a role in shifting future COVD-19 infection patterns from endemic to episodic.
Joseph J, Ylade M, Daag J, Aogo R, Crisostomo M, Mpingabo P BMC Infect Dis. 2024; 24(1):1042.
PMID: 39333882 PMC: 11430261. DOI: 10.1186/s12879-024-09672-8.
Lidenge S, Yalcin D, Bennett S, Ngalamika O, Kweyamba B, Mwita C Viruses. 2024; 16(3).
PMID: 38543814 PMC: 10975915. DOI: 10.3390/v16030448.
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
Abela I, Schwarzmuller M, Ulyte A, Radtke T, Haile S, Ammann P mBio. 2024; 15(2):e0272223.
PMID: 38270455 PMC: 10865973. DOI: 10.1128/mbio.02722-23.
Said K, Alsolami A, Alshammari K, Alshammari F, Alhallabi S, Alafnan S Diagnostics (Basel). 2024; 14(1).
PMID: 38201429 PMC: 10802668. DOI: 10.3390/diagnostics14010120.
Immune imprinting and next-generation coronavirus vaccines.
Huang C, Vishwanath S, Carnell G, Chan A, Heeney J Nat Microbiol. 2023; 8(11):1971-1985.
PMID: 37932355 DOI: 10.1038/s41564-023-01505-9.